- Conditions
- Cardiovascular Disease
- Interventions
- ticagrelor, prasugrel, Placebo
- Drug
- Lead sponsor
- Yochai Birnbaum
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 81
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
- Interventions
- Placebo Oral Tablet, Prasugrel Oral Tablet
- Drug
- Lead sponsor
- Elliot Israel, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Coronary Arterial Disease (CAD), Peripheral Vascular Disease
- Interventions
- Aspirin, P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
- Drug
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Coronary Artery Disease, Atherosclerosis, Stent Placement
- Interventions
- Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
- Drug · Device
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • New York, New York
- Conditions
- Coronary Artery Disease
- Interventions
- clopidogrel 75 mg, Prasugrel 5 mg
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel, Ticagrelor
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Post-polypectomy Bleeding, Anti-platelet Therapy, Colonoscopy
- Interventions
- Not listed
- Lead sponsor
- Dallas VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 715 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cardiovascular Diseases, Heart Diseases
- Interventions
- Prasugrel (CS-747), Clopidogrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Coronary Arteriosclerosis, Acute Coronary Syndromes
- Interventions
- Prasugrel, Clopidogrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Coronary Artery Disease
- Interventions
- PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 52
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 44 more
- Conditions
- Antiplatelet Therapy, Healthy Donors, Von Willebrand Disease (VWD)
- Interventions
- T-TAS PL Assay
- Diagnostic Test
- Lead sponsor
- Hikari Dx, Inc.
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Baltimore, Maryland
- Conditions
- Migraine Disease, Patent Foramen Ovale
- Interventions
- Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cardiovascular Diseases, Acute Coronary Syndrome
- Interventions
- clopidogrel, prasugrel
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 20 Years to 74 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Newark, Delaware • Baltimore, Maryland • Danville, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- Prasugrel ODT1 - Tablet, Prasugrel ODT2 - Tablet, Prasugrel ODT2 - Suspension
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Coronary Artery Disease, Peripheral Artery Disease
- Interventions
- Not listed
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Sickle Cell Disease
- Interventions
- Prasugrel (clinical formulation), Prasugrel (Orally Disintegrating Tablet [ODT])
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- Cangrelor, Clopidogrel, Prasugrel
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Bleeding Complications
- Interventions
- Clopidogrel, Prasugrel, Tricagrelor
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy
- Interventions
- ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Coronary Artery Disease
- Interventions
- Clopidogrel & Aspirin, Prasugrel & Aspirin, Placebo & Aspirin
- Drug
- Lead sponsor
- Cordis US Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Myocardial Infarction
- Interventions
- Prasugrel, Vorapaxar, Aspirin, Ticagrelor
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Sickle Cell Disease
- Interventions
- Prasugrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
- Conditions
- Coronary Artery Disease
- Interventions
- Cangrelor, Prasugrel
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Burlington, Vermont